Welcome to our dedicated page for Atara Biotherape SEC filings (Ticker: ATRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atara Biotherapeutics, Inc. (NASDAQ: ATRA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Atara is a T-cell immunotherapy company focused on allogeneic, off-the-shelf EBV-specific T-cell therapies for difficult-to-treat cancers and autoimmune conditions, and its filings provide detailed visibility into this business model, its financial condition, and key milestones.
Investors can use Atara’s Forms 10-K and 10-Q to review segment information, research and development spending, commercialization revenue from its agreement with Pierre Fabre Laboratories, and the impact of transferring substantially all tabelecleucel operational activities and costs to its partner. These periodic reports also discuss risk factors related to clinical development, regulatory outcomes, and the company’s evaluation of strategic alternatives such as potential mergers, asset sales, or other transactions.
Current reports on Form 8-K are particularly important for tracking material events at Atara. Recent 8-Ks referenced in the supplied materials include announcements of quarterly financial results and operational progress, regulatory and business updates on tabelecleucel (tab-cel or EBVALLO), and disclosure of a workforce reduction affecting approximately 29% of employees. These filings often incorporate press releases as exhibits, offering additional context on FDA interactions, BLA resubmissions, Priority Review status, and Complete Response Letters.
On this page, Stock Titan pairs Atara’s raw SEC filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand changes in cash runway, partnership economics, restructuring charges, and regulatory developments. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms appear promptly, while insider transaction reports on Form 4, when filed, can shed light on trading activity by Atara’s officers and directors.
By combining official filings with AI-generated explanations, this resource helps investors, analysts, and researchers interpret Atara’s disclosures on its EBV-focused T-cell platform, its collaboration with Pierre Fabre Laboratories, and its ongoing strategic review.
Atara Biotherapeutics (ATRA) filed a Form 144 reporting a proposed sale of 2,048 shares of common stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $25,169.92. The filing shows those shares were acquired on 08/15/2025 as settlement of vested restricted stock units issued under an S-8 registration plan, with payment noted as equity compensation for services rendered. The filer also reported a prior sale on 05/16/2025 of 2,218 shares for gross proceeds of $15,000.33. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Atara Biotherapeutics (ATRA) reported a pronounced change in its mid‑2025 financial position driven by transactions with Pierre Fabre and cost reductions. Total assets declined to $36.9 million at June 30, 2025 from $109.1 million at year‑end, and cash and cash equivalents were $16.9 million. Total liabilities fell to $71.9 million, and stockholders’ deficit improved to $(35.0) million.
Commercialization revenue for the six months ended June 30, 2025 was $115.7 million, reflecting recognition of deferred revenue tied to the transfer of manufacturing, inventory and related services to Pierre Fabre; deferred revenue declined from $95.1 million at year‑end to $1.6 million at June 30. Net income for the six months was $40.4 million versus a loss of $50.8 million a year earlier, producing basic earnings per share of $3.52 for the period. The company recorded restructuring charges of $11.3 million and a lease right‑of‑use impairment of $4.1 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional capital.
Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.